News Image

Is NYSE:NVO suited for dividend investing?

By Mill Chart

Last update: Mar 18, 2024

Take a closer look at NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO), a stock of interest to dividend investors uncovered by our stock screener. NYSE:NVO excels in fundamentals and provides a decent dividend, all while maintaining a reasonable valuation. Let's break it down further.

Assessing Dividend for NYSE:NVO

ChartMill assigns a Dividend Rating to every stock. This score ranges from 0 to 10 and evaluates the different dividend aspects, including the yield, the growth and sustainability. NYSE:NVO scores a 7 out of 10:

  • Compared to an average industry Dividend Yield of 4.00, NVO pays a better dividend. On top of this NVO pays more dividend than 91.54% of the companies listed in the same industry.
  • The dividend of NVO is nicely growing with an annual growth rate of 11.24%!
  • NVO has been paying a dividend for at least 10 years, so it has a reliable track record.
  • As NVO did not decrease their dividend in the past 5 years, we can say the dividend looks stable.
  • NVO pays out 37.96% of its income as dividend. This is a sustainable payout ratio.
  • The dividend of NVO is growing, but earnings are growing more, so the dividend growth is sustainable.

Analyzing Health Metrics

ChartMill employs its own Health Rating for stock assessment. This rating, ranging from 0 to 10, is calculated by examining various liquidity and solvency ratios. In the case of NYSE:NVO, the assigned 7 reflects its health status:

  • An Altman-Z score of 13.84 indicates that NVO is not in any danger for bankruptcy at the moment.
  • NVO has a better Altman-Z score (13.84) than 90.05% of its industry peers.
  • The Debt to FCF ratio of NVO is 0.39, which is an excellent value as it means it would take NVO, only 0.39 years of fcf income to pay off all of its debts.
  • NVO's Debt to FCF ratio of 0.39 is amongst the best of the industry. NVO outperforms 96.02% of its industry peers.
  • A Debt/Equity ratio of 0.19 indicates that NVO is not too dependend on debt financing.
  • The current and quick ratio evaluation for NVO is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.

Profitability Analysis for NYSE:NVO

ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NYSE:NVO has earned a 9 out of 10:

  • NVO has a better Return On Assets (26.61%) than 97.51% of its industry peers.
  • The Return On Equity of NVO (78.53%) is better than 98.51% of its industry peers.
  • NVO's Return On Invested Capital of 56.78% is amongst the best of the industry. NVO outperforms 99.00% of its industry peers.
  • NVO had an Average Return On Invested Capital over the past 3 years of 50.71%. This is significantly above the industry average of 16.40%.
  • The last Return On Invested Capital (56.78%) for NVO is above the 3 year average (50.71%), which is a sign of increasing profitability.
  • Looking at the Profit Margin, with a value of 36.03%, NVO belongs to the top of the industry, outperforming 95.52% of the companies in the same industry.
  • NVO has a Operating Margin of 44.16%. This is amongst the best in the industry. NVO outperforms 98.01% of its industry peers.
  • NVO has a better Gross Margin (84.60%) than 87.56% of its industry peers.

More Best Dividend stocks can be found in our Best Dividend screener.

Check the latest full fundamental report of NVO for a complete fundamental analysis.

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

NOVO-NORDISK A/S-SPONS ADR

NYSE:NVO (4/26/2024, 7:07:16 PM)

Premarket: 126.92 +0.07 (+0.06%)

126.85

+1.06 (+0.84%)

NVO News

News Image9 minutes ago - The Motley FoolBillionaire Investor Jim Simons Just Bought These 3 "Magnificent Seven" Stocks

The "Magnificent Seven" stocks dominate the artificial intelligence (AI) arena. One notable hedge fund manager has three in his top 10 holdings.

News Image22 hours ago - The Motley FoolIs Viking Therapeutics Incredibly Undervalued?

The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.

News Image2 days ago - The Motley FoolForget Nvidia, These Unstoppable Stocks Are Better Buys

These stocks have tremendous potential, and it doesn't depend on the growth prospects for artificial intelligence.

News Image2 days ago - The Motley Fool1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On

Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications.

News Image3 days ago - Market News VideoInteresting NVO Put And Call Options For June 7th
News Image4 days ago - ChartmillIs NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) a Strong Candidate for Quality Investing?

Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) qualifies as a quality stock.

News Image5 days ago - InvestorPlace3 Biotech Stocks With Skyrocketing Potential: April 2024

These three biotech stocks, with robust fundamentals and long-term prospects represent the sector’s finest at this time.

News Image5 days ago - The Motley FoolMeet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market

Lilly recently announced news that could solve a big problem.

News Image5 days ago - InvestorPlace3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains

These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly.

News Image5 days ago - The Motley FoolMissed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.

Good news could be just around the corner for two drugmakers not named Novo Nordisk.

News Image6 days ago - The Motley FoolBetter Buy: Pfizer vs. Viking Therapeutics

These two pharma stocks have followed distinct paths of late. Which is the better investment?

News Image6 days ago - InvestorPlace3 Stocks With the Potential to Surpass Analyst Expectations for 2024

These stocks to buy are set to surpass analyst expectations, with exciting product and service developments sparking unforeseen growth.

NVO Links
Follow us for more